Hyloris Pharmaceuticals (HYL) H1 2025 earnings summary

Executive summary

• Recurring royalties increased nearly 30% year-over-year to €2.9 million, reflecting strong commercial traction for three products.

• Portfolio expanded to 26 products and candidates, with four new additions in H1 2025 and a target of 30 by year-end.

• Achieved FDA approval for Tranexamic Acid RTU, completed pivotal trial for Dofetilide IV, and reported positive results for Atomoxetine liquid.

• Signed new international licensing agreements and advanced late-stage collaborations for Valacyclovir oral suspension and XTRAZA.

• Maintained financial discipline with a contained net loss of €3.5 million, equity of €28.9 million, and cash of €18.6 million.

Financial highlights

• Revenues for H1 2025 were €3.0 million, down from €4.2 million in H1 2024 due to the absence of milestone payments; royalties rose 30% year-over-year.

• Operating loss (EBIT) was €3.5 million, compared to €4.0 million in H1 2024.

• R&D expenses decreased 6% year-over-year, while G&A expenses dropped 30%.

• Cash and cash equivalents stood at €18.6 million as of June 30, 2025, down from €23.6 million at year-end 2024.

• Basic and diluted loss per share was €(0.13), compared to €(0.12) in H1 2024.

Outlook and guidance

• On track to expand the portfolio to 30 products and candidates by year-end 2025.

• Cash position and equity base provide funding for ongoing R&D and growth plans.

• Preference to out-license cardiovascular assets for U.S. distribution; access to financial and strategic partners if additional funding is needed.

• Additional strategic partnerships and out-licensing milestones anticipated in coming months.

• U.S. cardiovascular commercialization strategy under continued development.